CoChat

Postnatal Expansion of the Pancreatic β-Cell Mass Is Dependent on Survivin

Open access

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—Diabetes results from a deficiency of functional β-cells due to both an increase in β-cell death and an inhibition of β-cell replication. The molecular mechanisms responsible for these effects in susceptible individuals are mostly unknown. The objective of this study was to determine whether a gene critical for cell division and cell survival in cancer cells, survivin, might also be important for β-cells. RESEARCH DESIGN AND METHODS—We generated mice harboring a conditional deletion of survivin in pancreatic endocrine cells using mice with a Pax-6-Cre transgene promoter construct driving tissue-specific expression of Cre-recombinase in these cells. We performed metabolic studies and immunohistochemical analyses to determine the effects of a mono- and biallelic deletion of survivin. RESULTS—Selective deletion of survivin in pancreatic endocrine cells in the mouse had no discernible effects during embryogenesis but was associated with striking decreases in β-cell number after birth, leading to hyperglycemia and early-onset diabetes by 4 weeks of age. Serum insulin levels were significantly decreased in animals lacking endocrine cell survivin, with relative stability of other hormones. Exogenous expression of survivin in mature β-cells lacking endogenous survivin completely rescued the hyperglycemic phenotype and the decrease in β-cell mass, confirming the specificity of the survivin effect in these cells. CONCLUSIONS—Our findings implicate survivin in the maintenance of β-cell mass through both replication and antiapoptotic mechanisms. Given the widespread involvement of survivin in cancer, a novel role for survivin may well be exploited in β-cell regulation in diseased states, such as diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db08-0170

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Survivin expression becomes gradually restricted to β-cells after birth. A: Survivin expression in pancreatic endocrine and exocrine cells from E15.5 to P21, assessed by immunofluorescent staining of pancreatic tissue isolated from wild-type mice, using antibodies to survivin, β-catenin, Isl1, insulin (Ins), glucagon (Gluc), and somatostatin (Som). Survivin is expressed throughout the pancreatic epithelium at E15.5 (β-catenin+, Isl1+ cells), becomes gradually restricted to endocrine (Isl1+) cells in late embryogenesis (E19.5) and postnatally (P14), and then is further restricted to β-cells (Ins+) by P21. Magnification ×20. Bar = 20 μm. B: Analysis of expression of differentiation markers in pancreatic sections isolated from Pax6-cre;survivinlox/lox mice and their littermate controls. Comparisons between mutant (MUT) and littermate controls (WT) indicated similar patterns and levels of expression at E15.5 and E19.5. Magnification ×20. Bar = 20 μm. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)
FIG. 1. Survivin expression becomes gradually restricted to β-cells after birth. A: Survivin expression in pancreatic endocrine and exocrine cells from E15.5 to P21, assessed by immunofluorescent staining of pancreatic tissue isolated from wild-type mice, using antibodies to survivin, β-catenin, Isl1, insulin (Ins), glucagon (Gluc), and somatostatin (Som). Survivin is expressed throughout the pancreatic epithelium at E15.5 (β-catenin+, Isl1+ cells), becomes gradually restricted to endocrine (Isl1+) cells in late embryogenesis (E19.5) and postnatally (P14), and then is further restricted to β-cells (Ins+) by P21. Magnification ×20. Bar = 20 μm. B: Analysis of expression of differentiation markers in pancreatic sections isolated from Pax6-cre;survivinlox/lox mice and their littermate controls. Comparisons between mutant (MUT) and littermate controls (WT) indicated similar patterns and levels of expression at E15.5 and E19.5. Magnification ×20. Bar = 20 μm. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)CC BY-NC-ND · PubMed Central
FIG. 2. Loss of survivin results in insulin-deficient diabetes. A: Mean (±SD) random glucose levels in littermate control (survivinlox/+ or survivinlox/lox) mice (○, n = 8 at each time point) and homozygous survivin-deficient (Pax6-Cre;survivinlox/lox) mice (▪, n = 8 at each time point) at various ages after birth. *Significance at P < 0.01. B: Glucose tolerance test (mean ± SD) in 6-week-old male littermates. Control (○, n = 7) and homozygous survivin-deficient (▪, n = 7) mice were fasted for 5 h then injected with dextrose (2 g/kg body wt) intraperitoneally. *Significance at P < 0.05. C: Insulin challenge test in 4-week-old littermates. Four-week-old control (○, n = 3) and homozygous survivin-deficient (▪, n = 4) mice were injected with 0.75 unit/kg insulin (fed state). No statistically significant differences were found at any time point. D: Random serum insulin levels measured by enzyme-linked immunosorbent assay in age-matched animals at the indicated times. ○, insulin levels in individual control animals (n = 16); ▴, levels in individual Pax-6Cre;survivinlox/lox animals (n = 12). See supplementary Table 1 for individual values.
FIG. 2. Loss of survivin results in insulin-deficient diabetes. A: Mean (±SD) random glucose levels in littermate control (survivinlox/+ or survivinlox/lox) mice (○, n = 8 at each time point) and homozygous survivin-deficient (Pax6-Cre;survivinlox/lox) mice (▪, n = 8 at each time point) at various ages after birth. *Significance at P < 0.01. B: Glucose tolerance test (mean ± SD) in 6-week-old male littermates. Control (○, n = 7) and homozygous survivin-deficient (▪, n = 7) mice were fasted for 5 h then injected with dextrose (2 g/kg body wt) intraperitoneally. *Significance at P < 0.05. C: Insulin challenge test in 4-week-old littermates. Four-week-old control (○, n = 3) and homozygous survivin-deficient (▪, n = 4) mice were injected with 0.75 unit/kg insulin (fed state). No statistically significant differences were found at any time point. D: Random serum insulin levels measured by enzyme-linked immunosorbent assay in age-matched animals at the indicated times. ○, insulin levels in individual control animals (n = 16); ▴, levels in individual Pax-6Cre;survivinlox/lox animals (n = 12). See supplementary Table 1 for individual values.CC BY-NC-ND · PubMed Central
FIG. 3. Loss of insulin-producing cells in survivin-deficient animals. A: Insulin, glucagon, and somatostatin expression in 3- and 12-week-old animals, shown by immunochemical staining of pancreatic sections isolated from control mice and Pax-6Cre;survivinlox/lox littermates. Bars = 40 μm. B: Mean (±SD) serum glucagon levels measured by immunoassay in age-matched animals at the indicated times. ▪, control mice (n = 21); □, Pax-6-Cre;survivinlox/lox mice (n = 25). (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)
FIG. 3. Loss of insulin-producing cells in survivin-deficient animals. A: Insulin, glucagon, and somatostatin expression in 3- and 12-week-old animals, shown by immunochemical staining of pancreatic sections isolated from control mice and Pax-6Cre;survivinlox/lox littermates. Bars = 40 μm. B: Mean (±SD) serum glucagon levels measured by immunoassay in age-matched animals at the indicated times. ▪, control mice (n = 21); □, Pax-6-Cre;survivinlox/lox mice (n = 25). (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)CC BY-NC-ND · PubMed Central
FIG. 4. Loss of islet cell mass and nuclear abnormalities in survivin-deficient mice. A: Expansion of the endocrine cell mass after birth. Pancreatic tissue was isolated from age-matched animals at the indicated times. The mean (± SD) islet cell mass of control (▪, n = 8 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) and survivin-deficient (□, n = 7 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) tissues was calculated by point morphometry. *Significant (P < 0.001) difference. B: β-Cell size differences in affected animals. Pancreatic tissue isolated from animals at the indicated times was stained with H-E and visualized by light microscopy. Mutant β-cells with enlarged nuclei are indicated by arrows. Bars = 20 μm. C: Nuclear size measurements from B. ▪, control tissue (n = 5); □, survivin-deficient tissue (n = 5). *Significance at P < 0.001. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)
FIG. 4. Loss of islet cell mass and nuclear abnormalities in survivin-deficient mice. A: Expansion of the endocrine cell mass after birth. Pancreatic tissue was isolated from age-matched animals at the indicated times. The mean (± SD) islet cell mass of control (▪, n = 8 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) and survivin-deficient (□, n = 7 [P0], 3 [P7], 5 [P14], 4 [P21], and 4 [8W]) tissues was calculated by point morphometry. *Significant (P < 0.001) difference. B: β-Cell size differences in affected animals. Pancreatic tissue isolated from animals at the indicated times was stained with H-E and visualized by light microscopy. Mutant β-cells with enlarged nuclei are indicated by arrows. Bars = 20 μm. C: Nuclear size measurements from B. ▪, control tissue (n = 5); □, survivin-deficient tissue (n = 5). *Significance at P < 0.001. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)CC BY-NC-ND · PubMed Central
FIG. 5. Defects in replication and apoptosis pathways. A: PCNA staining of pancreatic tissues indicates a 50% decrease in the proliferation of islet cells isolated from survivin-deficient animals (□, n = 5) compared with their littermate controls (▪, n = 5). Data are mean (±SD) percentages of positive cells. *Significance at P < 0.05. B: Caspase 3 activity assays performed on islets isolated from 2-week-old mice indicate a two- to threefold increase in caspase 3 activation in islet cells isolated from survivin-deficient animals (□) compared with their littermate controls (▪). Data are mean (±SD) percentages of positive cells. *Significance at P < 0.05. C: Aberrant cell cycle progression in islet cells lacking survivin. Islet cells isolated from 2-week-old Pax6-cre;survivinlox/lox mice and their littermate controls were fixed, stained with propidium iodide, and analyzed by flow cytometry. Comparisons between survivin-deficient animals and their controls are shown. D: Fold changes in the expression of the indicated genes as determined by quantitative PCR of isolated islets at 1–2 weeks of age. ▪, Pax6-cre;survivinlox/lox cells in comparison with controls. Data are mean (±SD).
FIG. 5. Defects in replication and apoptosis pathways. A: PCNA staining of pancreatic tissues indicates a 50% decrease in the proliferation of islet cells isolated from survivin-deficient animals (□, n = 5) compared with their littermate controls (▪, n = 5). Data are mean (±SD) percentages of positive cells. *Significance at P < 0.05. B: Caspase 3 activity assays performed on islets isolated from 2-week-old mice indicate a two- to threefold increase in caspase 3 activation in islet cells isolated from survivin-deficient animals (□) compared with their littermate controls (▪). Data are mean (±SD) percentages of positive cells. *Significance at P < 0.05. C: Aberrant cell cycle progression in islet cells lacking survivin. Islet cells isolated from 2-week-old Pax6-cre;survivinlox/lox mice and their littermate controls were fixed, stained with propidium iodide, and analyzed by flow cytometry. Comparisons between survivin-deficient animals and their controls are shown. D: Fold changes in the expression of the indicated genes as determined by quantitative PCR of isolated islets at 1–2 weeks of age. ▪, Pax6-cre;survivinlox/lox cells in comparison with controls. Data are mean (±SD).CC BY-NC-ND · PubMed Central
FIG. 6. Survivin, under control of the RIP, rescues the diabetic phenotype and islet cell mass of the Pax6-Cre;survivinlox/lox mice. A: Mean (± SD) random glucose levels in Pax6-Cre;survivinlox/lox (n = 7) mice compared with Pax6-Cre;survivinlox/lox;RIP-SVV (n = 6), RIP-SVV (n = 5), and survivinlox/lox (SVVl/l) mice (n = 6) from 4 to 8 weeks after birth. *Significance at P < 0.05. B: Representative islet cell morphology of the mice in A at 12 weeks of age. Bar = 40 μm. C: Islet cell mass in RIP-SVV (▪, n = 4) and Pax6-Cre;RIP-SVV;survivinlox/lox (□, n = 4) mice. No statistically significant differences were found. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)
FIG. 6. Survivin, under control of the RIP, rescues the diabetic phenotype and islet cell mass of the Pax6-Cre;survivinlox/lox mice. A: Mean (± SD) random glucose levels in Pax6-Cre;survivinlox/lox (n = 7) mice compared with Pax6-Cre;survivinlox/lox;RIP-SVV (n = 6), RIP-SVV (n = 5), and survivinlox/lox (SVVl/l) mice (n = 6) from 4 to 8 weeks after birth. *Significance at P < 0.05. B: Representative islet cell morphology of the mice in A at 12 weeks of age. Bar = 40 μm. C: Islet cell mass in RIP-SVV (▪, n = 4) and Pax6-Cre;RIP-SVV;survivinlox/lox (□, n = 4) mice. No statistically significant differences were found. (Please see http://dx.doi.org/10.2337/db08-0170 for a high-quality digital representation of this image.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 38

Metadata

Authors
Jiang, Y., Nishimura, W., Devor-Henneman, D., Kusewitt, D., Wang, H., Holloway, M. P., Dohi, T., Sabo, E., Robinson, M. L., Altieri, D. C., Sharma, A., & Altura, R. A.
Affiliations
  • Nationwide Children's Hospital (US)
  • Joslin Diabetes Center (US)
  • The Ohio State University (US)
  • Brown University (US)
  • University of Massachusetts Chan Medical School (US)
  • Miami University (US)
Corresponding author
Altura, Rachel A.
Venue
Diabetes
Published
2008-10-01
Volume
57
Issue
10
Pages
2718-2727
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2116245644
Cited by
38
References
58
Citations by year
2024: 1 · 2022: 3 · 2020: 2 · 2017: 3 · 2015: 2 · 2014: 3 · 2013: 6 · 2012: 4
FWCI
4.92
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • National Heart, Lung, and Blood Institute (R01HL054131, R37HL054131, HL 54131)
  • National Cancer Institute (R01CA078810, CA-78810, R01CA090917, CA-90917)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R21DK078300, DK060127, R01DK060127, 1R21-DK-078300-01)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
survivin, pancreatic beta cells, beta-cell mass, postnatal development, conditional gene deletion, type 1 diabetes, hyperglycemia, insulin deficiency, beta-cell proliferation, beta-cell apoptosis, anti-apoptotic mechanisms, pancreatic endocrine cells
MeSH terms
Survivin, Animals, Diabetes Mellitus, Type 1, Female, Glucagon, Immunohistochemistry, Insulin, Islets of Langerhans, Male, Mice, Inbred Strains, Mice, Transgenic, Microtubule-Associated Proteins, Repressor Proteins, Somatostatin, Gene Deletion, Insulin-Secreting Cells, Inhibitor of Apoptosis Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.